Arana begins Phase II
Thursday, 11 December, 2008
Arana Therapeutics has begun its Phase II trial of its domain antibody ART621 for rheumatoid arthritis.
The trial, which will recruit 200 patients, will held in eight countries, including Australia, the US and India.
It will test the efficacy of ART621 in rheumatoid arthritis and will compare three doses of ART621 with a placebo in patients also taking methotrexate, a common anti-metabolite that inhibits the metabolism of folic acid.
Results are due in mid-2010.
Overuse of inhalers can increase heart attack risk
Overuse of reliever inhalers is associated with higher risks of developing and dying from...
Unhealthy Western diet could accelerate cognitive decline
An unhealthy Western-style diet is associated with a faster cognitive decline in people with a...
Cancer drug enters clinical trials based on a false mechanism
A cancer drug currently being tested in patients appears to have entered clinical trials based on...
